-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On February 4, sutimlimab, a potential new drug in Sanofi's R&D pipeline, was approved by the US FDA for the treatment of cold agglutinin disease (CAD)
The complement system is an important part of the innate immune system, consisting of more than 30 proteins, mainly found in the blood
Although as early as more than 100 years ago, humans have known the concept of complement
The data included in the CPM New Drug R&D Monitoring Database shows that there are nearly 60 complement-targeting drugs under active research globally, of which 9 are in Phase III clinical stage, 16 are in Phase II clinical stage, and 7 are in Phase II clinical stage.
In terms of targets, among the drugs entering the clinical research stage, there are the most drugs targeting C5 and its related receptors, with 14; a total of 5 drugs targeting complement factor D/H; 3 drugs targeting C3, 2 drugs each targeting C2 and serine protease peptidase
In terms of indications, although the indications under development are still mainly for rare diseases with approved first-in-class drugs, applications in some common diseases are also being actively explored, including the complications of COVID-19 caused by the new crown epidemic.
Table 1.
Source: CPM New Drug Development Monitoring Database
